Every intervention Outliyr has scored for memory, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for memory; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
50 of 95 evaluated interventions score 3.0+ out of 10 for memory · 9 comparisons
Avgerinos 2018 reports 6 RCTs; short-term memory and processing speed; vegetarian and elderly amplification. Dolan 2019 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Creatine…
Memory benefits are mostly indirect through attention, working-memory, and arousal regulation rather than a dedicated memory protocol. Westwood 2025 found limited neuropsychological transfer overall, with processing speed more consistent than memory. Preserve…
Mori 2009 anchors the most relevant signal. Lion's Mane fits memory when the goal is gentle mushroom-based support for cognition, mood, nerve biology, or gut-immune signaling over weeks. The score stays bounded…
Slutsky 2010 anchors the most relevant signal. Magnesium fits memory when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are…
Memory is the primary clinical endpoint for PS. Positive bovine cortex trials contrast with more mixed soy and sunflower data, including Kato-Kataoka 2010 subgroup findings and Friling 2025 largely null total-cohort results.…
Rodriguez 2016 supports the strongest part of the claim. The existing rationale points to this narrower claim: The human memory signal is small but real enough to preserve the v0 score: this…
Naeser 2011 found cognitive gains in chronic mild TBI cases after transcranial LED treatment. Memory claims are still emerging because trials are small and populations are specific. The mechanism makes sense through…
The existing rationale points to this narrower claim: Aerobic exercise supports memory through hippocampal blood flow, BDNF, metabolic health, and better sleep quality. The v0.x direction remains reasonable, but v1.0. That does…
Hamaya 2025 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Memory score is driven by long-term dementia associations rather than direct memory RCTs. this verified source…
Memory support is strongest in animal models: Dolotov et al. 2006 found hippocampal BDNF and TrkB changes with conditioned-learning effects, while Ellis et al. 2020 supports hypoxia-stress memory protection in rats. That…
Memory support is plausible via cognitive-aging and post-stroke literature. Hadanny 2020 shows improvements clustered in attention, processing speed, and executive function rather than pure memory. Boussi-Gross 2014 reports memory improvement in chronic…
Harrison 2009 anchors the most relevant signal. Rapamycin fits memory when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded because human longevity endpoints remain…
Shahmirzadi 2020 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Preclinical hippocampal LTP and synaptic tagging signal from this verified source is interesting but still mouse-only.…
Some RCT evidence for working memory improvement with RF training, but Rosendo da Cunha e Silva 2026 review tempers expectations. The score stays bounded because HRV Biofeedback evidence for memory can depend…
Soh 2024 anchors the most relevant signal. Glycine fits memory because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because many…
Dhillon 2024 reports 25-article systematic review; mixed preliminary clinical evidence, heterogeneity, and need for stronger trials. Zhou 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide…
Tassorelli et al. 2018 supports a plausible benefit. Small human studies suggest possible memory effects, but the 2024 epilepsy cognition meta-analysis did not show a reliable memory advantage, keeping this exploratory. The…
The evidence points to a plausible use case without proving a universal response. Zhang et al. 2025 is the best anchor here because it reports 25 randomized trials, 1486 participants and improved…
Memory is the endpoint the compound was built around, and it is measured in humans only through MMSE, a screening instrument rather than a memory battery. The foundational pharmacology work reported that…
Baker 2012 reported memory-related improvement after GHRH analog therapy in older adults and MCI. The score stays moderate because replication and disease-specific neurodegeneration outcomes remain limited. The score stays bounded because Tesamorelin…
The evidence points to a plausible use case without proving a universal response. Mann G et al. 2026 is the best anchor here because it reports five studies meta-analyzed, 997 participants and…
McCoy 2013 anchors the most relevant signal. Dihexa fits memory only as a research-chemical hypothesis around synaptogenesis and memory circuits, not as a proven human nootropic. The score stays bounded because the…
The most relevant studies involve memory tasks, cognitive impairment, or working-memory endpoints. The strongest support comes from Dinda B. et al. 2015, but the practical rating stays bounded by study size, replication,…
The signal is conditional. Working-memory improvements appear mainly in caffeine-combination trials such as Owen 2008 and Haskell 2008. Standalone memory effects remain modest. That makes L-Theanine more defensible when memory is a…
Liu 2024 reports 11 RCTs; 346 healthy participants; significant improvements reported across fatigue, cognition, and exercise-efficiency endpoints overall; endpoint details are limited. The score stays conditional because Astaxanthin still needs better outcome…
The Yau 2024 pilot in 19 people with mild cognitive impairment found improved verbal learning in the treated group, and Zajac 2025 reported gains in subjective prospective memory at 25 mg per…
The most relevant studies involve memory tasks, cognitive impairment, or working-memory endpoints. The strongest support comes from Cohen P. et al. 2020, but the practical rating stays bounded by study size, replication,…
The most relevant studies involve memory tasks, cognitive impairment, or working-memory endpoints. The strongest support comes from Isaacson et al. 1991, but the practical rating stays bounded by study size, replication, and…
The most relevant studies involve memory tasks, cognitive impairment, or working-memory endpoints. The strongest support comes from Copani A. et al. 1992, but the practical rating stays bounded by study size, replication,…
Semaglutide has no proven human memory benefit in this report, despite active interest in GLP-1 brain biology. Perkovic 2024 and other outcome trials support systemic risk reduction, not memory enhancement. The pathway…
Resveratrol's memory effect appears limited to that specific cohort; no replication has been reported in men, younger women, or high-performing healthy adults. The evidence tier remains low, as the signal emerges from…
Memory benefit remains unproven in humans without diabetes. The theoretical AMPK and insulin-sensitivity rationale is offset by B12-depletion risk and lack of direct memory RCT evidence.
No dedicated tirzepatide memory trial was audit-verified; score reflects indirect metabolic-risk improvement rather than proven cognitive enhancement.
Dehydration can impair short-term cognitive performance; rehydration restores baseline rather than enhancing memory beyond normal.
Aerobic fitness supports hippocampal health and memory over time. Norwegian 4x4 is a plausible route to that adaptation, but memory is not a primary measured endpoint in the foundational 4x4 trials.
No direct memory evidence was verified. Any cognitive relevance is indirect through protein adequacy, frailty reduction, or metabolic health.
Yurko-Mauro 2010 supports DHA in age-related cognitive decline, but this does not establish Alzheimer's prevention or meaningful benefit for already-optimized adults.
J-147 restored probe-trial memory to control levels and rescued contextual fear conditioning in symptomatic aged mice (Prior et al. 2013). Consistent and repeated in animals, but never measured in a person.
Schwarz 2022 did not hit the primary memory endpoint, so the memory score stays modest despite mechanistic interest.
Memory remains a 4 because Alzheimer's mouse and neuronal-injury models do not yet translate into human memory outcomes. Tucker 2024 is the newest signal, and it should be read as preclinical.
No direct memory evidence. Whole-body vibration should not be promoted as a cognitive enhancer for healthy adults.
Memory tracks the same dementia data as the broader cognition picture, which is why it earns a moderate score with a real caveat rather than a high one. The pooled Alzheimer's cognitive…
Hippocampal LTP support from Mikhaylova/Behnisch 2007 (PMID 17854844) is suggestive but no human memory-battery RCT exists.
Memory support is mainly preclinical. BDNF and ethanol-memory models in Kolik 2019 fit the claim, but there is no robust human memory trial.
No direct memory RCT data were identified. Any memory claim would be extrapolated from mood and stress changes and should remain low-confidence.
Memory claims should stay conservative because the strongest clinical test was null. The T Trials cognition substudy did not show memory benefit despite selecting older men with low testosterone and memory complaints.
Rides on the same single long Theracurmin trial as cognition. Not replicated, not something to count on.
Dopaminergic protection may preserve memory circuits in animal models. No human memory endpoint is verified in the audit.
Preclinical hippocampal protection is directionally relevant, but the audit found no human memory endpoint trial for SS-31 or elamipretide.
Memory is the one cognitive endpoint pine pollen has actually moved in a model. Mao 2012 reported improved memory alongside lower IL-6 and TNF-alpha in D-galactose-aged mice given 500 to 1500 mg/kg,…
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 13 of 50 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Creatine Monohydrate | Not priced yet | ||
| Neurofeedback | Not priced yet | ||
| Lion’s Mane | $20–$40 | 3 g/day fruiting body extract | Over the counter |
| Magnesium | $10–$20 | 200-400 mg glycinate elemental | Over the counter |
| Phosphatidylserine | $20–$50 | 300 mg/day total, split as 100 mg three times daily or 300 mg once daily with food | Over the counter |
| Methylene Blue | $13–$40 | 0.5-5 mg oral | Over the counter |
| Red Light Therapy | $17–$43 | 10-20 min at 6-12 inches, full chest/face/back rotation | Over the counter |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Infrared Sauna | $36–$73 | 55-60 degrees C, 20-30 min | Over the counter |
| Semax | $12–$60 | 300-600 mcg/day of 0.1% spray | Grey market |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Molecular Hydrogen | Not priced yet | ||
| Vagus Nerve Stimulation | $4–$8 | 10-20 min auricular tVNS at comfortable perceptible intensity | Over the counter |
| Saffron | Not priced yet | ||
| Noopept (Omberacetam) | $5–$27 | 20 mg | Grey market |
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| Modafinil | $18–$35 | 200 mg oral tablet | Prescription |
| Dihexa | $30–$60 | 8-12 mg/day sublingual | Research use only |
| Sabroxy (Oroxylum indicum Extract) | Not priced yet | ||
| L-Theanine | $3–$8 | 200 mg L-theanine + 100 mg caffeine | Over the counter |
| Astaxanthin | Not priced yet | ||
| Ergothioneine | Not priced yet | ||
| Piracetam (Nootropil) | $8–$20 | 2.4-4.8 g | Grey market |
| Aniracetam | $10–$25 | 750-1,500 mg | Grey market |
| Oxiracetam | $15–$40 | 800-2,400 mg | Grey market |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Resveratrol | Not priced yet | ||
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Electrolytes | Not priced yet | ||
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Essential Amino Acids | Not priced yet | ||
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| J-147 | Not priced yet | ||
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Cerebrolysin | $500–$900 | About 30 mL per day IV | Grey market |
| Bromantane (Ladasten) | $12–$30 | 30 mg | Grey market |
| Selank | $30–$60 | 0.15% intranasal spray, roughly 1-3 sprays per nostril per day depending on actuation size | Grey market |
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| Curcumin | $15–$40 | 500 mg curcuminoids | Over the counter |
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| SS-31 (Elamipretide) | $200–$500 | 5-10 mg/day subcutaneous | Grey market |
| Pine Pollen | $20–$45 | 5 to 10 g powder per day | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
Ranked by the live Focus and cognition subrating, not the overall score. Methylene blue leads at 6.5–7.0/10 despite a lower overall, 6.0–6.5/10. Bromantane climbs from ninth to fourth.…
Semax scores 7.1/10 against noopept's 6.2/10 and wins five of the eight use cases both reports score. Noopept is oral, cheaper at $5 to $27 a month, and…
Cerebrolysin scores 6.0–6.5/10 and P-21 scores 5.0–5.5/10, and the gap is entirely about human data. Cerebrolysin has thousands of trial participants, contested by two independent Cochrane reviews. P-21…
Neither, yet. Both have zero human trials, zero human pharmacokinetics and research-only access. PE-22-28 scores 4.5–5.0/10 and dihexa 4.0–4.5/10, and the gap is entirely safety: dihexa potentiates the…
Epitalon, if sleep is the question. It scores sleep quality 6.5–7.0/10 against pinealon's 1.5–2.0/10, because it acts on the pineal gland and melatonin output while pinealon is a…
Bromantane scores 7.0–7.5/10 and modafinil 5.5–6.0/10, and they answer different questions. Modafinil is the faster and better-documented wakefulness drug when sleep debt or diagnosed sleepiness is the problem.…
Semax scores 7.0–7.5/10 and cerebrolysin 6.0–6.5/10. Semax wins cognition, neuroplasticity and nerve regeneration, costs an estimated $12 to $60 a month, and goes up your nose. Cerebrolysin wins…
Semax scores 7.0–7.5/10 against dihexa's 4.0–4.5/10, and that gap is real. Semax wins every cognitive use case we scored and carries human stroke data. Dihexa has zero human…
NMN scores 6.0–6.5/10, NR 6.0–6.5/10, and direct NAD+ 5.0–5.5/10. The oral precursors win on evidence and price. NMN takes blood sugar and metabolic health. NR takes cardiovascular and…
Creatine Monohydrate, at 7.0–7.5 out of 10 for memory. Avgerinos 2018 reports 6 RCTs; short-term memory and processing speed; vegetarian and elderly amplification.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.5–6.0 out of 10 for memory.
Dihexa scores 5.5–6.0 out of 10 for memory but only 4.0–4.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
50 of the 95 interventions evaluated for memory score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
